Cargando…

Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy

Pediatric patients with differentiated thyroid cancer (DTC) tend to have more advanced disease at presentation, for which more aggressive radioiodine (RAI) treatment would be commonly recommended. Several previous studies recommended dosimetry to calculate the optimal activity of RAI in pre-pubertal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ping, Wang, Li, Huang, Rui, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402880/
https://www.ncbi.nlm.nih.gov/pubmed/32756134
http://dx.doi.org/10.1097/MD.0000000000021398
_version_ 1783566844967256064
author Dong, Ping
Wang, Li
Huang, Rui
Li, Lin
author_facet Dong, Ping
Wang, Li
Huang, Rui
Li, Lin
author_sort Dong, Ping
collection PubMed
description Pediatric patients with differentiated thyroid cancer (DTC) tend to have more advanced disease at presentation, for which more aggressive radioiodine (RAI) treatment would be commonly recommended. Several previous studies recommended dosimetry to calculate the optimal activity of RAI in pre-pubertal children and in children with a significant distant metastasis. This study aimed to evaluate the effect of empirical RAI treatment for DTC on bone marrow function in pre-pubertal children and adolescents. DTC patients aged ≤ 18 years receiving empirical RAI treatment with complete blood count data before and after treatment were included and divided into pre-pubertal and pubertal groups. Blood count values at baseline and 1.5–3 months, 3–6 months, and 6–12 months after RAI treatment were compared. The effect of demographic, clinical, and laboratory variables on bone marrow function were assessed. We included 83 patients (113 treatments). At diagnosis, pre-pubertal children had more aggressive tumor features, including tumor size (P = .045) and distant metastases (P = .037). Approximately 51% to 96% of hypocellular bone marrow, and 11% to 14% of anemia were observed in the pre-pubertal and pubertal groups, with a majority of mild (Grade 1–2) and minority of moderate (Grade 3) bone marrow suppression. No significant differences in bone marrow function or Common Terminology Criteria for Adverse Events (CTCAE) grades were found between the pre-pubertal and pubertal groups after RAI treatment. None of the clinical factors tested were found to be significant predictors for bone marrow suppression after RAI treatment. Empirical RAI treatment for DTC in pre-pubertal children and adolescents causes mild to moderate bone marrow suppression with limited clinical significance. With adequate preparations for RAI treatment, empirical high activities (150–200 mCi) could be safe and well tolerated by both pre-pubertal and pubertal patients with DTC.
format Online
Article
Text
id pubmed-7402880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-74028802020-08-14 Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy Dong, Ping Wang, Li Huang, Rui Li, Lin Medicine (Baltimore) 6800 Pediatric patients with differentiated thyroid cancer (DTC) tend to have more advanced disease at presentation, for which more aggressive radioiodine (RAI) treatment would be commonly recommended. Several previous studies recommended dosimetry to calculate the optimal activity of RAI in pre-pubertal children and in children with a significant distant metastasis. This study aimed to evaluate the effect of empirical RAI treatment for DTC on bone marrow function in pre-pubertal children and adolescents. DTC patients aged ≤ 18 years receiving empirical RAI treatment with complete blood count data before and after treatment were included and divided into pre-pubertal and pubertal groups. Blood count values at baseline and 1.5–3 months, 3–6 months, and 6–12 months after RAI treatment were compared. The effect of demographic, clinical, and laboratory variables on bone marrow function were assessed. We included 83 patients (113 treatments). At diagnosis, pre-pubertal children had more aggressive tumor features, including tumor size (P = .045) and distant metastases (P = .037). Approximately 51% to 96% of hypocellular bone marrow, and 11% to 14% of anemia were observed in the pre-pubertal and pubertal groups, with a majority of mild (Grade 1–2) and minority of moderate (Grade 3) bone marrow suppression. No significant differences in bone marrow function or Common Terminology Criteria for Adverse Events (CTCAE) grades were found between the pre-pubertal and pubertal groups after RAI treatment. None of the clinical factors tested were found to be significant predictors for bone marrow suppression after RAI treatment. Empirical RAI treatment for DTC in pre-pubertal children and adolescents causes mild to moderate bone marrow suppression with limited clinical significance. With adequate preparations for RAI treatment, empirical high activities (150–200 mCi) could be safe and well tolerated by both pre-pubertal and pubertal patients with DTC. Wolters Kluwer Health 2020-07-31 /pmc/articles/PMC7402880/ /pubmed/32756134 http://dx.doi.org/10.1097/MD.0000000000021398 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6800
Dong, Ping
Wang, Li
Huang, Rui
Li, Lin
Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title_full Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title_fullStr Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title_full_unstemmed Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title_short Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
title_sort bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy
topic 6800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402880/
https://www.ncbi.nlm.nih.gov/pubmed/32756134
http://dx.doi.org/10.1097/MD.0000000000021398
work_keys_str_mv AT dongping bonemarrowsuppressioninpediatricpatientswithdifferentiatedthyroidcancerfollowingempiricalradioiodinetherapy
AT wangli bonemarrowsuppressioninpediatricpatientswithdifferentiatedthyroidcancerfollowingempiricalradioiodinetherapy
AT huangrui bonemarrowsuppressioninpediatricpatientswithdifferentiatedthyroidcancerfollowingempiricalradioiodinetherapy
AT lilin bonemarrowsuppressioninpediatricpatientswithdifferentiatedthyroidcancerfollowingempiricalradioiodinetherapy